The Volpara Health Technologies Ltd (ASX: VHT) share price went 3% on Friday after completing its acquisition.
Volpara describes itself as a ‘MedTech Software as a Service’ company that was founded in 2009 on research conducted at Oxford University. Its software is used for screening clinics to provide feedback on breast density, compression, dose and quality. Its VolparaEnterprise business provides role-specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.
Volpara’s Acquisition
Volpara has completed the acquisition of the Seattle-based MRS Systems.
The acquisition of MRS Systems increases the number of US breast clinics to which the company has access to from around 400 to over 2,000, being an increase of around 400%. Apart from the obvious immediate financial improvements this brings large amounts of additional data to optimise its analysis.
Volpara also said that it will provide stronger technical expertise, a significant increase of annual recurring revenue (ARR), accelerated sales through cross-selling opportunities and increased potential average revenue per user (ARPU) through new products.
Volpara certainly seems to be one to watch, but it has a price to match that shorter term potential. The leading growth shares in the free report below could be better priced buys for growth.
[ls_content_block id=”14947″ para=”paragraphs”]
[ls_content_block id=”18380″ para=”paragraphs”]
